Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | GGT1 | P19440 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433657 | 1.00 | FOLH1 (0.49) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL433656 | 1.00 | FOLH1 (0.49) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL30540130 | 0.93 | FOLH1 (0.49) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL4087629 | 0.88 | FOLH1 (0.47) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL4100264 | 0.88 | FOLH1 (0.47) | FOLH1GSRRNPEPMMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6010125 | 0.87 | FOLH1 (0.46) | FOLH1GSRRNPEPMMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6010135 | 0.87 | FOLH1 (0.46) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL28450260 | 0.86 | SLC6A5 (0.52) | FOLH1SLC6A5TLR2 | |
| SCHEMBL9924207 | 0.85 | FOLH1 (0.45) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL6010377 | 0.83 | FOLH1 (0.41) | FOLH1GSRRNPEPMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582625-B2 | Methods for treating neuroblastoma | USWM, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250186380-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | Cancer Prevention Pharmaceuticals (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250127742-A1 | METHODS FOR TREATING NEUROBLASTOMA | OAKTREE FUND ADMINISTRATION, LLC | 2025-04-24 | — | — | US | disclosed |
| US-20240165063-A1 | METHODS FOR TREATING NEUROBLASTOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | disclosed |
| EP-3968971-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | Cancer Prevention Pharmaceuticals, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096240-A | Method for treating familial adenomatous polyposis | 癌症预防制药股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20220040130-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | CANCER PREVENTION PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20120095058-A1 | Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-04-19 | — | — | US | disclosed |
| WO-1992005190-A1 | DEOXYHYPUSYL HYDROXYLASE INHIBITORS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095058-A1 | Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses | EIF2B5, EIF5B, EIF2B1 | FOLH1 4083/4885GSR 3239/4885RNPEP 1427/4885 |
| US-12582625-B2 | Methods for treating neuroblastoma | ODC1, DDC, CD2 | FOLH1 201/4885GSR 2068/4885RNPEP 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.